High-activity catechol-O-methyltransferase allele is more prevalent in polysubstance abusers.

Allelic variants at the catechol-O-methyltransferase (COMT) locus are candidates to contribute to genetic components of interindividual differences in vulnerability to substance abuse. COMT plays a prominent role in dopaminergic circuits important for drug reward, and COMT alleles encode enzymes whose activities vary from three- to four-fold. We compared COMT allele frequencies in control research volunteers reporting insignificant lifetime use of addictive substances with those in volunteers reporting substantial polysubstance use. Homozygosity for the high-activity COMT allele was found in 18% of controls, 31% of volunteers with high lifetime substance use, and 39% meeting DSMIII-R substance abuse criteria [odds ratio (relative risks) 2.0 (control vs. use; 95% confidence interval 1.2-3.5; P < 0.013) and 2.8 (control vs. DSM; 1.3-6.1; P < 0.008)]. Individuals with the high-activity COMT variant may have greater genetic vulnerability to drug abuse.

[1]  G. Uhl,et al.  Indicators of genetic and environmental influences in drug abusing individuals. , 1996, Drug and alcohol dependence.

[2]  S. Higuchi,et al.  Dopamine transporter gene polymorphism and alcoholism. , 1995, Biochemical and biophysical research communications.

[3]  G. Uhl,et al.  Retained cocaine conditioned place preference in D1 receptor deficient mice. , 1995, Neuroreport.

[4]  A. Jalanko,et al.  Cloning and characterization of human placental catechol-O-methyltransferase cDNA. , 1991, DNA and cell biology.

[5]  F. Bloom,et al.  Psychopharmacology: The Fourth Generation of Progress , 1995 .

[6]  R. Weinshilboum,et al.  Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. , 1996, Pharmacogenetics.

[7]  Henry R. Kranzler,et al.  Genetic Association between Dopamine Transporter Protein Alleles and Cocaine-Induced Paranoia , 1995, Neuropsychopharmacology.

[8]  R Kucherlapati,et al.  Association of codon 108/158 catechol-O-methyltransferase gene polymorphism with the psychiatric manifestations of velo-cardio-facial syndrome. , 1996, American journal of medical genetics.

[9]  S. Aksoy,et al.  Catechol O-methyltransferase pharmacogenetics: photoaffinity labelling and western blot analysis of human liver samples. , 1993, Pharmacogenetics.

[10]  G. Bennett.  Substance Abuse: Pharmacologic, Developmental and Clinical Perspectives , 1983 .

[11]  I. Kopin,et al.  Monoamine oxidase and catecholamine metabolism. , 1994, Journal of neural transmission. Supplementum.

[12]  I. Ulmanen,et al.  Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. , 1995, Biochemistry.

[13]  R Pickens,et al.  Genetic vulnerability to drug abuse. The D2 dopamine receptor Taq I B1 restriction fragment length polymorphism appears more frequently in polysubstance abusers. , 1992, Archives of general psychiatry.

[14]  S. Faraone,et al.  Genetic influences on DSM-III-R drug abuse and dependence: a study of 3,372 twin pairs. , 1996, American journal of medical genetics.

[15]  M. Owen,et al.  No evidence for allelic association between schizophrenia and a polymorphism determining high or low catechol O-methyltransferase activity. , 1996, The American journal of psychiatry.

[16]  G. Uhl,et al.  Dopamine transporter gene polymorphisms are not associated with polysubstance abuse , 1993, Biological Psychiatry.

[17]  A. Jalanko,et al.  Cloning and Characterization of Human Placental Catechol--Methyltransferase cDNA , 1991 .

[18]  Z Dembic,et al.  Human catechol-O-methyltransferase: cloning and expression of the membrane-associated form. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[19]  T. Kiviluoto,et al.  Genomic organization of the human catechol O-methyltransferase gene and its expression from two distinct promoters. , 1994, European Journal of Biochemistry.

[20]  M. McGue,et al.  Common genetic mechanisms in alcohol, drug, and mental disorder comorbidity. , 1995, Drug and alcohol dependence.

[21]  R. Weinshilboum,et al.  Human liver catechol‐O‐methyltransferase pharmacogenetics , 1990, Clinical pharmacology and therapeutics.

[22]  R T Borchardt,et al.  Catechol O-methyltransferase. , 1981, Methods in enzymology.

[23]  R. Weinshilboum,et al.  Genetics of red cell COMT activity: analysis of thermal stability and family data. , 1981, American journal of medical genetics.

[24]  G. Uhl.  Association strategies in substance abuse. , 1994, EXS.

[25]  H. Jörnvall,et al.  Toward a Molecular Basis of Alcohol Use and Abuse , 1994, Experientia.

[26]  E P Noble,et al.  Allelic association of the D2 dopamine receptor gene with cocaine dependence. , 1993, Drug and alcohol dependence.